Showing results (201-210 of 237) with videos related to
Sort By:
Pageof 24
Bone Marrow Transplantation|November 12, 2024
Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTKavita Raj, Diderik-Jan Eikema, Sarah Lawless, et al.Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 9, 2019
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationDonal McLornan, Richard Szydlo, Linda Koster, et al.Clinical Lymphoma, Myeloma & Leukemia|July 12, 2017
Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMTMichel van Gelder, Dimitris Ziagkos, Liesbeth de Wreede, et al.JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.Hemasphere|May 22, 2025
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalitionAnna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.Bone Marrow Transplantation|April 10, 2026
Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMTAlexandros Kanellopoulos, Linda Koster, Hugues de Lavallade, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2018
Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host DiseaseChristoph Groth, Lenneke F J van Groningen, Tiago R Matos, et al.Frontiers in Immunology|November 15, 2023
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 studyArmin Gerbitz, Regina Gary, Michael Aigner, et al.Pageof 24